Summary:
- The U.S. FDA has approved Tremfya (guselkumab), an IL-23 inhibitor, for the treatment of adult patients with moderately to severely active Crohn's disease.
- Tremfya is the first and only IL-23 inhibitor to offer both subcutaneous and intravenous induction options, providing flexibility in treatment administration.
- This approval expands the use of Tremfya, which was previously approved for the treatment of plaque psoriasis and psoriatic arthritis, to now include Crohn's disease, a chronic inflammatory bowel disease.